FiercePharma: Profectus BioSciences Announces Initiation of Clinical Trial Evaluating its Therapeutic HIV Vaccine in Support of the "Cure Agenda"
An NIAID-conducted Phase 1 Study Will Assess the Safety and Immunogenicity of the Profectus Multi-Antigen HIV DNA Vaccine in Formulation with Profectus' GENEVAX™ IL-12 Adjuvant when Delivered by ...
Profectus BioSciences Announces Initiation of Clinical Trial Evaluating its Therapeutic HIV Vaccine in Support of the "Cure Agenda"
Business Wire: Enable, Profectus Form Partnership and Announce Rebate Deal Management Platform Acquisition
Enable expands in Australia with acquisition of Profectus' leading Rebate Deal Management (RDM) software platform; Profectus secures a stake in Enable while partnership facilitates global market entry ...
Business Wire: Profectus Capital Goes Live With Scienaptic’s AI-Powered Credit Decisioning Platform
BANGALORE, India--(BUSINESS WIRE)--Scienaptic AI, a leading global AI-powered credit decision platform provider, announced today that Profectus Capital is now live on its platform. As a part of ...
FiercePharma: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
BALTIMORE, Dec. 9, 2015 /PRNewswire/ -- Profectus BioSciences, Inc., a clinical-stage vaccine company developing innovative vaccines for the prevention and treatment of infectious diseases and the ...
Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses